Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)
CNY 19.28
(0.47%)
CNY 19.28
(0.47%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 66.48 Million CNY | -13.71% |
| 2022 | 71.38 Million CNY | -28.55% |
| 2021 | 111.25 Million CNY | -6.74% |
| 2020 | 111.56 Million CNY | 10.27% |
| 2019 | 99.6 Million CNY | 12.18% |
| 2018 | 87.74 Million CNY | 21.53% |
| 2017 | 73.79 Million CNY | 6.5% |
| 2016 | 67.35 Million CNY | 0.0% |
| 2013 | 42.87 Million CNY | 37.91% |
| 2012 | 32.57 Million CNY | 5.74% |
| 2011 | 30.98 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 12.11 Million CNY | -28.85% |
| 2024 Q2 | 9.88 Million CNY | 6.37% |
| 2024 Q1 | 4.64 Million CNY | 65.44% |
| 2023 Q2 | 5.87 Million CNY | 545.11% |
| 2023 FY | - CNY | -13.71% |
| 2023 Q1 | -1.31 Million CNY | 73.55% |
| 2023 Q4 | 1.56 Million CNY | -90.89% |
| 2023 Q3 | 17.2 Million CNY | 193.01% |
| 2022 FY | - CNY | -28.55% |
| 2022 Q4 | -4.98 Million CNY | -159.98% |
| 2022 Q3 | 8.31 Million CNY | -35.51% |
| 2022 Q2 | 12.89 Million CNY | -43.03% |
| 2022 Q1 | 22.63 Million CNY | 7.53% |
| 2021 Q1 | 27.03 Million CNY | 24.16% |
| 2021 Q3 | 7.11 Million CNY | -76.7% |
| 2021 FY | - CNY | -6.74% |
| 2021 Q2 | 30.54 Million CNY | 12.99% |
| 2021 Q4 | 21.04 Million CNY | 195.7% |
| 2020 Q1 | 12.44 Million CNY | -32.65% |
| 2020 FY | - CNY | 10.27% |
| 2020 Q4 | 21.77 Million CNY | -47.65% |
| 2020 Q2 | 29.01 Million CNY | 133.21% |
| 2020 Q3 | 41.59 Million CNY | 43.36% |
| 2019 Q1 | 23.08 Million CNY | 0.0% |
| 2019 Q3 | 33.93 Million CNY | 67.39% |
| 2019 Q2 | 20.27 Million CNY | -12.19% |
| 2019 FY | - CNY | 12.18% |
| 2019 Q4 | 18.47 Million CNY | -45.56% |
| 2018 FY | - CNY | 21.53% |
| 2017 FY | - CNY | 6.5% |
| 2016 FY | - CNY | 0.0% |
| 2013 FY | - CNY | 37.91% |
| 2012 FY | - CNY | 5.74% |
| 2011 FY | - CNY | 0.0% |